CA3036557A1 - Beta-lactamase inhibitor compounds - Google Patents

Beta-lactamase inhibitor compounds Download PDF

Info

Publication number
CA3036557A1
CA3036557A1 CA3036557A CA3036557A CA3036557A1 CA 3036557 A1 CA3036557 A1 CA 3036557A1 CA 3036557 A CA3036557 A CA 3036557A CA 3036557 A CA3036557 A CA 3036557A CA 3036557 A1 CA3036557 A1 CA 3036557A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
alkoxy
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3036557A
Other languages
English (en)
French (fr)
Inventor
Gregory S. Basarab
Bill Moss
Janelle Comita-Prevoir
Thomas Francois Durand-Reville
Lise GAUTHIER
John O'donnell
Jan Romero
Ruben Tommasi
Jeroen Cunera Verheijen
Frank Wu
Xiaoyun Wu
Jing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entasis Therapeutics Ltd
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Priority to CA3314454A priority Critical patent/CA3314454A1/en
Publication of CA3036557A1 publication Critical patent/CA3036557A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0892—Compounds with a Si-O-N linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3036557A 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds Pending CA3036557A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3314454A CA3314454A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395464P 2016-09-16 2016-09-16
US62/395,464 2016-09-16
US201762456423P 2017-02-08 2017-02-08
US62/456,423 2017-02-08
PCT/US2017/051692 WO2018053215A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3314454A Division CA3314454A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Publications (1)

Publication Number Publication Date
CA3036557A1 true CA3036557A1 (en) 2018-03-22

Family

ID=60083416

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3036557A Pending CA3036557A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds
CA3314454A Pending CA3314454A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3314454A Pending CA3314454A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Country Status (24)

Country Link
US (1) US10800778B2 (enExample)
EP (1) EP3512851B1 (enExample)
JP (2) JP6997178B2 (enExample)
KR (2) KR102537340B1 (enExample)
CN (2) CN109715630B (enExample)
AU (1) AU2017325863B2 (enExample)
CA (2) CA3036557A1 (enExample)
CY (1) CY1125826T1 (enExample)
DK (1) DK3512851T3 (enExample)
ES (1) ES2927986T3 (enExample)
HR (1) HRP20221217T1 (enExample)
HU (1) HUE060282T2 (enExample)
IL (2) IL289686B2 (enExample)
LT (1) LT3512851T (enExample)
MA (1) MA46242A (enExample)
MX (2) MX392515B (enExample)
PH (1) PH12019500558B1 (enExample)
PL (1) PL3512851T3 (enExample)
PT (1) PT3512851T (enExample)
SG (1) SG11201901658PA (enExample)
SI (1) SI3512851T1 (enExample)
SM (1) SMT202200397T1 (enExample)
TW (1) TWI773687B (enExample)
WO (1) WO2018053215A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN112209928B (zh) * 2019-07-10 2023-02-17 华东理工大学 共价键标记丝氨酸类beta-内酰胺酶的试剂及制备和应用
CN110898999A (zh) * 2019-11-26 2020-03-24 中国矿业大学 一种煤焦油基煤泥浮选药剂及其制备方法
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
CN111790439B (zh) * 2020-07-29 2022-12-27 成都能特科技发展有限公司 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用
WO2022047603A1 (en) 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
EP4319760A4 (en) * 2021-04-05 2025-01-08 Qpex Biopharma, Inc. CEFTIBUTENE DOSAGE REGIMEN
US12410166B2 (en) 2021-05-07 2025-09-09 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023206580A1 (en) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
US20230398101A1 (en) * 2022-06-09 2023-12-14 Fleurir Abx Llc Co-agents as Therapy Against Anaerobic Pathogens
CN118271319B (zh) * 2022-12-30 2025-02-28 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
CN118772145B (zh) * 2023-04-04 2025-10-10 上海医药工业研究院有限公司 一种二氮杂双环辛烯化合物的制备方法
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法
WO2025106662A1 (en) * 2023-11-15 2025-05-22 Entasis Therapeutics, Inc. Preparation of boronic acid intermediates useful for the preparation of compounds for treating bacterial infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
ATE177099T1 (de) 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RS59255B1 (sr) * 2010-04-20 2019-10-31 Fujifilm Toyama Chemical Co Ltd Derivat hidroksaminske kiseline
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
CA2842777C (en) 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ， インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
NZ706734A (en) 2012-09-03 2016-05-27 Wockhardt Ltd Pharmaceutical compositions useful for the treatment or control of bacterial infections
CN104994860A (zh) 2013-02-06 2015-10-21 阿斯利康(瑞典)有限公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
TWI690317B (zh) * 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
CA2980085A1 (en) * 2015-03-31 2016-10-06 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
KR20230007830A (ko) * 2021-07-06 2023-01-13 현대자동차주식회사 고강성 저선팽창 열가소성 수지 조성물 및 이를 포함하는 성형체

Also Published As

Publication number Publication date
SI3512851T1 (sl) 2022-11-30
AU2017325863B2 (en) 2021-08-19
WO2018053215A1 (en) 2018-03-22
AU2017325863A1 (en) 2019-03-14
IL289686B (en) 2022-11-01
PH12019500558B1 (en) 2023-09-08
PL3512851T3 (pl) 2022-11-14
IL265276B (en) 2022-02-01
JP6997178B2 (ja) 2022-02-03
IL289686B2 (en) 2023-03-01
US10800778B2 (en) 2020-10-13
KR102537340B1 (ko) 2023-05-26
EP3512851A1 (en) 2019-07-24
NZ751016A (en) 2025-02-28
KR20190043630A (ko) 2019-04-26
SMT202200397T1 (it) 2022-11-18
IL265276A (en) 2019-05-30
JP7281527B2 (ja) 2023-05-25
HRP20221217T1 (hr) 2022-12-23
MX385507B (es) 2025-03-18
CN109715630A (zh) 2019-05-03
MX2019003060A (es) 2019-07-08
JP2022046563A (ja) 2022-03-23
IL289686A (en) 2022-03-01
MA46242A (fr) 2019-07-24
TW201823207A (zh) 2018-07-01
PT3512851T (pt) 2022-10-11
PH12019500558A1 (en) 2019-07-29
LT3512851T (lt) 2022-10-25
CN114591223B (zh) 2025-01-24
MX392515B (es) 2025-03-24
HUE060282T2 (hu) 2023-02-28
US20190202832A1 (en) 2019-07-04
CN109715630B (zh) 2022-02-22
DK3512851T3 (en) 2022-10-17
ES2927986T3 (es) 2022-11-14
EP3512851B1 (en) 2022-07-06
MX2021010077A (es) 2022-05-23
KR20230078830A (ko) 2023-06-02
CY1125826T1 (el) 2026-02-25
KR102667828B1 (ko) 2024-05-20
BR112019005053A2 (pt) 2019-06-18
TWI773687B (zh) 2022-08-11
SG11201901658PA (en) 2019-04-29
JP2019532928A (ja) 2019-11-14
CA3314454A1 (en) 2026-08-05
CN114591223A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
JP7281527B2 (ja) ベータラクタマーゼ阻害剤化合物
TWI597281B (zh) β－內醯胺酶抑制劑化合物
EP3426248B1 (en) Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
JP2018104463A (ja) メタロ−β−ラクタマーゼ阻害剤としての３−テトラゾリル−ベンゼン−１，２−ジスルホンアミド誘導体
JP7598594B2 (ja) オキソ置換化合物
JP7550421B2 (ja) オキソ置換化合物からなる医薬
HK40011101A (en) Beta-lactamase inhibitor compounds
HK40011101B (en) Beta-lactamase inhibitor compounds
BR112019005053B1 (pt) Compostos inibidores de beta-lactamase, usos dos mesmos, composição farmacêutica, e processo para formação de um composto
EA044428B1 (ru) Соединения-ингибиторы бета-лактамаз
EA037916B1 (ru) Соединения-ингибиторы бета-лактамаз
NZ791470A (en) Beta-lactamase inhibitor compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220803

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250721

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250721

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260210

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20260610

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260615

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260615